CJC-1295 + Ipamorelintwo signals, one growth-hormone pulse — the classic secretagogue stack

A coherent idea — with components studied and the combo not.

The CJC-1295 + ipamorelin stack rests on a genuinely sound physiological idea: pair a GHRH-receptor signal with a ghrelin-receptor signal so they converge on the pituitary's GH-release machinery from two directions. The individual arms have real human pharmacology — CJC-1295 DAC has a healthy-adult PK/PD study, ipamorelin has IV PK/PD plus a Phase 2 postoperative-ileus trial. What's missing is a controlled human outcome trial of the actual no-DAC + ipamorelin wellness stack. Both are unapproved, compounding is suspended after FDA review, and both are WADA-prohibited. The single most important technical point: no-DAC and DAC CJC-1295 are not interchangeable.

Two doors to the same GH-release room.

Growth-hormone release from pituitary somatotrophs is governed by two opposing-but-complementary upstream signals: GHRH (which drives synthesis and release) and ghrelin (which amplifies and synchronizes pulses). The stack supplies a synthetic version of each — CJC/Mod GRF for the GHRH receptor, ipamorelin for the ghrelin/GHS receptor — so they converge on GH release from two pathways. The receptor pharmacology of each arm is well-established (Grade C/P); the combined synergy is plausible but not outcome-proven (Grade D/P); and the downstream IGF-1, glucose, and immunogenicity pathways are the practical risk story.

Pulse-timed by design — and no-DAC is the default.

There is no approved dosing protocol for this stack. The models below are research frameworks, not treatment instructions. The default calculator identity is no-DAC CJC / Modified GRF(1-29) paired with ipamorelin, dosed in pulses (typically nightly) because the no-DAC arm clears in ~30 minutes. DAC-CJC is deliberately handled as a separate conceptual route — its 5.8–8.1-day half-life makes nightly no-DAC logic dangerous to apply to it. The calculator works in micrograms of a 1:1 blend and validates arithmetic only.

Combinations — the stack is itself a combination.

CJC-1295 + ipamorelin is already a combination — that's the whole point. The pairings discussed beyond it (training, sleep timing, metabolic programs) are mechanistically reasonable framings, not proven protocols, and every one is Grade D because no controlled trial tested them. The genuinely important content here is the hard constraint: a GH-secretagogue stack should never be combined with exogenous GH, IGF-1 analogs, insulin/insulin secretagogues, or anabolic agents without specialist oversight — and it's contraindicated outright in active malignancy, pregnancy, uncontrolled diabetes, and intracranial-hypertension-type symptoms.

"Relatively well tolerated" — is not "proven safe".

The small human studies of the individual components reported relatively mild side-effect profiles, and the CJC-1295 DAC study found no serious adverse reactions at the doses tested. But that describes limited, short-term, single-agent data — not the chronic combination use seen in practice. The FDA has flagged both peptides for significant safety risks: immunogenicity (worsened by ipamorelin's unnatural amino acids complicating characterization), impurity/aggregation, and specific serious adverse events (increased heart rate and systemic vasodilatory reaction for CJC-1295; deaths of unclear causality in IV ipamorelin's postoperative-ileus context). Layered on top are the predictable GH-axis effects — glucose intolerance, fluid retention, IGF-1 overexposure.

Practical safety framework

Contraindications & cautions

Solid component pharmacology — no stack outcome trial.

The evidence here is real but specific: it's about the individual arms, not the combination. CJC-1295 DAC has a healthy-adult PK/PD study (Teichman 2006: GH up 2–10× for ≥6 days, IGF-1 up 1.5–3× for 9–11 days, t½ 5.8–8.1 days). Ipamorelin has human IV PK/PD modeling (Gobburu 1999) and a Phase 2 randomized postoperative-ileus trial (Beck 2014). The receptor pharmacology of both is well-characterized preclinically (the CJC-1295 albumin-bioconjugate paper; Raun's selective-secretagogue work). What does not exist is a robust controlled human outcome trial of the actual no-DAC CJC + ipamorelin wellness stack — so the combination is mechanistically plausible but clinically unproven, and the safety uncertainty is genuine.

The stack among the GH secretagogues.

The two arms of this stack sit on opposite sides of the GH-secretagogue family: CJC/Mod GRF is a GHRH analog (like sermorelin and tesamorelin), while ipamorelin is a ghrelin/GHS-receptor agonist (like MK-677 and the older GHRP-2/6). The contrast that matters: sermorelin is the short-acting GHRH parent, tesamorelin is the one FDA-approved GHRH analog (for HIV lipodystrophy), and ipamorelin is the "cleaner" GHS with less cortisol/prolactin spillover than GHRP-2/6. The table keeps both the mechanism split and the approval reality honest.

Related peptides.

The same stack, three depths.

Source register.

Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. The firmest sources are the human PK/PD studies of the individual components (Grade B — CJC-1295 DAC; ipamorelin IV PK/PD and the postoperative-ileus RCT), with receptor pharmacology established preclinically (Grade C/P). There is no Grade-A or even direct Grade-B source for the exact no-DAC + ipamorelin wellness stack — its standing is mechanistic (Grade D/P). Regulatory, identity, and anti-doping records are Grade D. The grade pattern honestly shows component evidence outrunning combination evidence.

More GH Axis peptides & tools.